NOVANOVA
US • —
$0.00
P/E
—
PEG
—
FCF Yield
—
Rev Growth YoY
+16.6% YoY
Gross Margin
44.9%
Health Score
2/10
D/E Ratio
4.63
Confidence
LOW
Business Snapshot
A relatively small biotechnology company focused on developing and commercializing treatments for hemophilia and other bleeding disorders. The company operates in the highly competitive hemophilia therapeutics market, where it faces established players with approved products and advanced pipeline assets. With a market cap that is not calculable from available data and limited revenue disclosure, the company appears to be a development-stage entity with significant operational risk. A defining characteristic is its high cash burn rate and negative profitability, typical of clinical-stage biotechs that have yet to achieve sustainable commercial sales.
Financial Health
The company's financial position shows severe strain, with a net margin of -43.8% indicating that the business is deeply unprofitable at the net income level. Gross margin stands at 44.9%, suggesting the company has some gross profit generation but it is insufficient to cover operating expenses...
Risk Assessment
- DEBT / LIQUIDITY — Debt/equity of 4.63x is extremely high, indicating a highly leveraged capital structure that increases financial risk.
- EARNINGS QUALITY — Net margin of -43.8% confirms the company is deeply unprofitable, with operating losses eroding shareholder equity.
- LIQUIDITY — Current ratio of 0.78x signals that current liabilities exceed current assets, raising near-term solvency concerns.
- PROFITABILITY — Return on equity of -21.1% shows the company is destroying shareholder value at a rapid pace.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed....
The company's financial position shows severe strain, with a net margin of -43.8% indicating that the business is deeply unprofitable at the net income level. Gross margin stands at 44.9%, suggesting the company has some gross profit generation but it is insufficient to cover operating expenses. The balance sheet is highly distressed, with a debt/equity ratio of 4.63x, meaning the company carries over four times as much debt as shareholder equity, and a current ratio of 0.78x, indicating that current liabilities exceed current assets and immediate liquidity risk is present. Free cash flow data is not available, but the negative return on equity of -21.1% confirms the company is destroying shareholder value rather than generating returns. Overall, the financial health is precarious, with high leverage and negative margins leaving the company vulnerable to dilution or restructuring if it cannot raise additional capital or achieve profitability.
- DEBT / LIQUIDITY — Debt/equity of 4.63x is extremely high, indicating a highly leveraged capital structure that increases financial risk. - EARNINGS QUALITY — Net margin of -43.8% confirms the company is deeply unprofitable, with operating losses eroding shareholder equity. - LIQUIDITY — Current ratio of 0.78x signals that current liabilities exceed current assets, raising near-term solvency concerns. - PROFITABILITY — Return on equity of -21.1% shows the company is destroying shareholder value at a rapid pace. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives